• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cannabis based medicines and cannabis dependence: A critical review of issues and evidence.基于大麻的药物和大麻依赖:问题和证据的批判性回顾。
J Psychopharmacol. 2021 Jul;35(7):773-785. doi: 10.1177/0269881120986393. Epub 2021 Feb 17.
2
Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective.性别的依赖性大麻和大麻素的影响:转化视角。
Neuropsychopharmacology. 2018 Jan;43(1):34-51. doi: 10.1038/npp.2017.140. Epub 2017 Jul 17.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users.加拿大药用大麻使用者队列中的大麻使用行为和焦虑及抑郁症状的流行率。
J Psychiatr Res. 2019 Apr;111:134-139. doi: 10.1016/j.jpsychires.2019.01.024. Epub 2019 Jan 31.
5
Cannabis in patients with Parkinson's disease in Argentina. A cross sectional study.阿根廷帕金森病患者中的大麻。一项横断面研究。
Parkinsonism Relat Disord. 2020 Sep;78:66-67. doi: 10.1016/j.parkreldis.2020.06.033. Epub 2020 Jun 29.
6
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review.医用大麻作为精神障碍治疗手段的有效性和安全性如何?一项系统性综述。
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):87-105. doi: 10.1007/s00406-019-00984-4. Epub 2019 Jan 31.
7
Introduction to Cannabis Special Issue.大麻特刊引言。
J Dual Diagn. 2020 Jan-Mar;16(1):1-2. doi: 10.1080/15504263.2019.1708551. Epub 2020 Jan 6.
8
Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain.理解医用大麻和基于大麻的药物治疗慢性非癌症疼痛的证据。
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):135-144. doi: 10.1007/s00406-018-0960-9. Epub 2019 Jan 11.
9
Cannabis in Parkinson's Disease: The Patients' View.帕金森病中的大麻:患者观点。
J Parkinsons Dis. 2021;11(1):309-321. doi: 10.3233/JPD-202260.
10
Cannabis and Epilepsy.大麻与癫痫
J Dual Diagn. 2020 Jan-Mar;16(1):75-82. doi: 10.1080/15504263.2019.1645372. Epub 2019 Aug 6.

引用本文的文献

1
Cannabinoids for the prevention of chemotherapy-induced nausea and vomiting in oncological therapy: a systematic review.大麻素类药物在肿瘤治疗中预防化疗引起的恶心和呕吐:一项系统评价
J Cancer Surviv. 2025 Aug 12. doi: 10.1007/s11764-025-01876-4.
2
A constrained disorder principle-based second-generation artificial intelligence digital medical cannabis system: A real-world data analysis.基于受限紊乱原理的第二代人工智能数字医用大麻系统:真实世界数据分析
J Public Health Res. 2025 Jun 9;14(2):22799036251337640. doi: 10.1177/22799036251337640. eCollection 2025 Apr.
3
Predictors of medical and non-medical motives of cannabis use in Finland: A cross-sectional survey study.芬兰大麻使用的医学和非医学动机的预测因素:一项横断面调查研究。
iScience. 2025 Apr 22;28(5):112503. doi: 10.1016/j.isci.2025.112503. eCollection 2025 May 16.
4
Daily Impact of Medical Cannabis on Anxiety and Sleep Quality in Older Adults.医用大麻对老年人焦虑和睡眠质量的每日影响
Psychiatry. 2025 May 15:1-15. doi: 10.1080/00332747.2025.2484827.
5
[Recommendations of the DGRh Committee on Complementary Medicine and Nutrition on the application of selected phytotherapeutic drugs and herbal medicines in rheumatology].[德国风湿病学会补充医学与营养委员会关于某些植物治疗药物和草药在风湿病学中的应用建议]
Z Rheumatol. 2025 Mar;84(2):152-163. doi: 10.1007/s00393-024-01612-w. Epub 2025 Feb 3.
6
3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract.3D打印软胶囊:一种用于富含大麻二酚的大麻提取物的新型给药系统。
Gels. 2024 Nov 26;10(12):770. doi: 10.3390/gels10120770.
7
Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts.医用大麻产品的临床益处与安全性:天然提取物的叙述性综述
Pain Ther. 2024 Oct;13(5):1063-1094. doi: 10.1007/s40122-024-00643-0. Epub 2024 Aug 3.
8
A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance.一项半自然主义、开放性标签研究,旨在考察规定医疗大麻使用对模拟驾驶表现的影响。
J Psychopharmacol. 2024 Mar;38(3):247-257. doi: 10.1177/02698811241229524. Epub 2024 Feb 8.
9
Attitudes of Swiss psychiatrists towards cannabis regulation and medical use in psychiatry: a cross-sectional study.瑞士精神科医生对大麻监管及在精神病学中医疗用途的态度:一项横断面研究。
J Cannabis Res. 2023 Dec 6;5(1):40. doi: 10.1186/s42238-023-00210-y.
10
The potential for medicinal cannabis to help manage challenging behaviour in people with intellectual disability: A perspective review.药用大麻在帮助智力残疾人士管理挑战性行为方面的潜力:观点综述。
J Psychopharmacol. 2023 Dec;37(12):1201-1208. doi: 10.1177/02698811231209192. Epub 2023 Nov 8.

本文引用的文献

1
An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK?医用大麻监管制度评估:英国能吸取哪些经验教训?
Med Cannabis Cannabinoids. 2020 Jan 15;3(1):76-83. doi: 10.1159/000505028. eCollection 2020 Aug.
2
The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage.医用大麻对患有背痛的间歇性和慢性阿片类药物使用者的影响:大麻如何减少阿片类药物处方用量。
Cannabis Cannabinoid Res. 2020 Sep 2;5(3):263-270. doi: 10.1089/can.2019.0039. eCollection 2020.
3
Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.大麻二酚用于治疗大麻使用障碍:一项2a期、双盲、安慰剂对照、随机、适应性贝叶斯试验。
Lancet Psychiatry. 2020 Oct;7(10):865-874. doi: 10.1016/S2215-0366(20)30290-X. Epub 2020 Jul 28.
4
Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users.在一个大型大麻使用者社区样本中,娱乐性和医疗性大麻使用存在重叠模式。
Compr Psychiatry. 2020 Oct;102:152188. doi: 10.1016/j.comppsych.2020.152188. Epub 2020 Jun 6.
5
Medical cannabis in the UK: From principle to practice.英国的医用大麻:从原则到实践。
J Psychopharmacol. 2020 Sep;34(9):931-937. doi: 10.1177/0269881120926677. Epub 2020 Jun 10.
6
The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial.新型选择性剂量大麻吸入器治疗慢性疼痛患者的药代动力学、疗效和安全性:一项随机、双盲、安慰剂对照试验。
Eur J Pain. 2020 Sep;24(8):1505-1516. doi: 10.1002/ejp.1605. Epub 2020 Jun 12.
7
A Balanced Approach for Cannabidiol Use in Chronic Pain.大麻二酚用于慢性疼痛的平衡方法。
Front Pharmacol. 2020 Apr 30;11:561. doi: 10.3389/fphar.2020.00561. eCollection 2020.
8
Evaluating the co-use of opioids and cannabis for pain among current users using hypothetical purchase tasks.评估当前使用者在假设购买任务中同时使用阿片类药物和大麻治疗疼痛的情况。
J Psychopharmacol. 2020 Jun;34(6):654-662. doi: 10.1177/0269881120914211. Epub 2020 Apr 8.
9
Mapping cannabis potency in medical and recreational programs in the United States.绘制美国医疗和娱乐用大麻效力图。
PLoS One. 2020 Mar 26;15(3):e0230167. doi: 10.1371/journal.pone.0230167. eCollection 2020.
10
What Do You Know About Maryjane? A Systematic Review of the Current Data on the THC:CBD Ratio.你对玛丽珍(大麻的俗称)了解多少?对 THC:CBD 比值现有数据的系统综述。
Subst Use Misuse. 2020;55(8):1223-1227. doi: 10.1080/10826084.2020.1731547. Epub 2020 Mar 3.

基于大麻的药物和大麻依赖:问题和证据的批判性回顾。

Cannabis based medicines and cannabis dependence: A critical review of issues and evidence.

机构信息

Drug Science, St Peter's House, London, UK.

Neuropsychopharmacology Unit, Centre for Psychiatry, Imperial College London, London, UK.

出版信息

J Psychopharmacol. 2021 Jul;35(7):773-785. doi: 10.1177/0269881120986393. Epub 2021 Feb 17.

DOI:10.1177/0269881120986393
PMID:33593117
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8278552/
Abstract

Cannabis has been legalised for medical use in an ever-increasing number of countries. A growing body of scientific evidence supports the use of medical cannabis for a range of therapeutic indications. In parallel with these developments, concerns have been expressed by many prescribers that increased use will lead to patients developing cannabis use disorder. Cannabis use disorder has been widely studied in recreational users, and these findings have often been projected onto patients using medical cannabis. However, studies exploring medical cannabis dependence are scarce and the appropriate methodology to measure this construct is uncertain. This article provides a narrative review of the current research to discern if, how and to what extent, concerns about problems of dependence in recreational cannabis users apply to prescribed medical users. We focus on the main issues related to medical cannabis and dependence, including the importance of dose, potency, cannabinoid content, pharmacokinetics and route of administration, frequency of use, as well as set and setting. Medical and recreational cannabis use differs in significant ways, highlighting the challenges of extrapolating findings from the recreational cannabis literature. There are many questions about the potential for medical cannabis use to lead to dependence. It is therefore imperative to address these questions in order to be able to minimise harms of medical cannabis use. We draw out seven recommendations for increasing the safety of medical cannabis prescribing. We hope that the present review contributes to answering some of the key questions surrounding medical cannabis dependence.

摘要

大麻在越来越多的国家被合法化用于医疗用途。越来越多的科学证据支持将医用大麻用于一系列治疗适应症。随着这些发展,许多处方医生担心,增加使用量将导致患者出现大麻使用障碍。大麻使用障碍在娱乐性使用者中得到了广泛研究,这些发现经常被投射到使用医用大麻的患者身上。然而,探索医用大麻依赖的研究很少,衡量这一结构的适当方法也不确定。本文对当前的研究进行了叙述性综述,以了解在多大程度上、如何以及在多大程度上,娱乐性大麻使用者对依赖问题的担忧适用于规定的医用使用者。我们专注于与医用大麻和依赖相关的主要问题,包括剂量、效力、大麻素含量、药代动力学和给药途径、使用频率以及环境和情境的重要性。医用和娱乐性大麻的使用有很大的不同,这突出了从娱乐性大麻文献中推断研究结果的挑战。关于医用大麻使用是否会导致依赖,存在许多问题。因此,必须解决这些问题,以便能够将医用大麻使用的危害降到最低。我们提出了七点增加医用大麻处方安全性的建议。我们希望本综述有助于回答围绕医用大麻依赖的一些关键问题。